Despite advances in supportive care and ventilator management, the most severe cases of acute lung injury/ acute respiratory distress syndrome (ALI/ARDS) continue to cause unacceptably high mortality rates in afflicted patients. [1, 2] Because effective pharmacologic intervention for ALI/ARDS is not available, [3, 4] improved understanding of the underlying pathophysiology is needed to develop targeted therapies. A critical early step in the pathogenesis of ALI/ARDS is the disruption of the lung vascular endothelial cell (EC) barrier by inflammatory stimuli, leading to pulmonary edema and subsequent respiratory ABSTRACT Acute lung injury (ALI) is characterized by inflammatory disruption of the alveolar-vascular barrier, resulting in severe respiratory compromise. Inhibition of the intercellular messenger protein, Group V phospholipase A 2 (gVPLA 2 ), blocks vascular permeability caused by LPS both in vivo and in vitro. In this investigation we studied the mechanism by which recombinant gVPLA 2 increases permeability of cultured human pulmonary endothelial cells (EC). Exogenous gVPLA 2 (500 nM), a highly hydrolytic enzyme, caused a significant increase in EC permeability that began within minutes and persisted for >10 hours. However, the major hydrolysis products of gVPLA 2 (Lyso-PC, Lyso-PG, LPA, arachidonic acid) did not cause EC structural rearrangement or loss of barrier function at concentrations <10 µM. Higher concentrations (> 30 µM) of these membrane hydrolysis products caused some increased permeability but were associated with EC toxicity (measured by propidium iodide incorporation) that did not occur with barrier disruption by gVPLA 2 (500 nM). Pharmacologic inhibition of multiple intracellular signaling pathways induced by gVPLA 2 activity (ERK, p38, PI3K, cytosolic gIVPLA 2 ) also did not prevent EC barrier disruption by gVPLA 2 . Finally, pretreatment with heparinase to prevent internalization of gVPLA 2 did not inhibit EC barrier disruption by gVPLA 2 . Our data thus indicate that gVPLA 2 increases pulmonary EC permeability directly through action as a membrane hydrolytic agent. Disruption of EC barrier function does not depend upon membrane hydrolysis products, gVPLA 2 internalization, or upregulation of downstream intracellular signaling.
of phospholipids [7, 8] and have been implicated in the pathogenesis of ALI in both animals [9] and patients. [10, 11] At least 10 different sPLA 2 enzymes with varying tissue distributions and phospholipase activities have been identified in mammals. [7] Recent data implicate a functional role for the 14 kDa secretory group V PLA 2 (gVPLA 2 ) enzyme in ALI pathophysiology. Inhibition of gVPLA 2 by specific blocking antibody [12] or pharmacologic inhibition [13] significantly attenuates vascular permeability caused by LPS in mice. In addition, deletion of the gene encoding gVPLA 2 in mice (pla2g5 -/knockout) blocks increases in multiple indices of lung injury after LPS. [12] Studies performed in vitro using cultured human pulmonary EC have demonstrated that disruption of the endothelial barrier by LPS can be blocked by inhibition of gVPLA 2 . [14] Moreover, the extracellular application of recombinant gVPLA 2 directly increases permeability of cultured human pulmonary EC. [14] Accordingly, prior studies strongly support an important mechanistic role for gVPLA 2 in the development of ALI-associated permeability both in vivo and in vitro. However, the mechanism by which gVPLA 2 increases EC permeability remains unclear.
The objective of this present study was to further characterize in vitro the potential pathway(s) responsible for disruption of pulmonary EC barrier function by gVPLA 2 . We hypothesize that one of three putative mechanisms might account for the development of EC barrier dysfunction caused by gVPLA 2 : (1) direct outer membrane hydrolysis; (2) secondary effects induced by products of gVPLA 2 membrane hydrolysis; and (3) induction of intracellular signaling pathways. It is likely that direct hydrolysis of the EC outer membrane by gVPLA 2 physically disrupts its integrity to increase permeability. The second possibility is that the products of membrane hydrolysis generated by gVPLA 2 are the primary agents that initiate downstream signaling events that result in EC barrier dysfunction. gVPLA 2 activity generates multiple products with potential biologic effects, including free fatty acid, arachidonic acid (AA), lysophosphatidylcholine (lyso-PC), lysophosphatidylglycerol (lyso-PG), lysophosphatidic acid (LPA), and others. [7, 8] A final possibility is that gVPLA 2 activity at the EC membrane induces intracellular signaling pathways to produce downstream effects (e.g., junctional complex disruption) resulting in barrier dysfunction.
In this study, we now demonstrate that the primary membrane hydrolysis products generated by gVPLA 2 do not duplicate the increased permeability caused by gVPLA 2 itself in cultured pulmonary EC. In addition, multiple intracellular signaling pathways induced by gVPLA 2 in pulmonary EC do not participate in barrier disruption. Thus, our data indicate that gVPLA 2 increases pulmonary EC permeability through direct hydrolytic action at the EC membrane and provide mechanistic insights into an important inflammatory signal that participates in the generation of vascular leak during ALI syndromes.
MAtERIAlS ANd MEtHodS

Reagents
Recombinant human gVPLA 2 was purchased from Cayman Chemical (Ann Arbor, Mich.). Arachidonic acid, lyso-PC, lyso-PG, LPA were obtained from Avanti Polar Lipids (Alabaster, Ala.). Pharmacologic inhibitors UO126, SB203580, TFMK, and LY294002 were obtained from EMD Chemicals (Gibbstown, N.J.). Heparinase I was obtained from Sigma-Aldrich Chemical (St. Louis, Mo.). Antibodies were obtained as follows: pan-ERK, phospho-ERK, pan-p38, phospho-p38, pan-AKT, phospho-AKT, pan-gIVaPLA 2 , phospho-gIVaPLA 2 from Cell Signaling (Beverly, Mass.), mouse anti-VEcadherin antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.). Texas-Red phalloidin was obtained from Invitrogen (Carlsbad, Calif.). All other reagents were obtained from Sigma unless otherwise noted.
Cell culture
Human pulmonary artery endothelial cells (HPAEC) and human lung microvascular endothelial cells (HLMVEC) were obtained from Lonza (Walkersville, Md.) and cultured according to the manufacturer's instructions as previously described. [15] EC (Passages 6-9) were grown in Endothelial Growth Medium-2 (EGM-2) at 37°C in a 5% CO 2 incubator. The medium was changed 1 day prior to experimentation. transendothelial monolayer electrical resistance EC were grown to confluency in polycarbonate wells containing evaporated gold microelectrodes, and Transendothelial monolayer electrical resistance (TER) measurements were performed using an electrical cellsubstrate impedance sensing system (ECIS; Applied Biophysics, Troy, N.Y.) as previously described in detail. [16] TER values from each microelectrode were expressed as normalized resistance and pooled as discrete time points and plotted versus time as the mean±SEM.
dextran transwell permeability assay
A transendothelial permeability assay was performed as per the manufacturer's instructions utilizing labeled tracer flux across confluent EC grown on confluent polycarbonate filters (Vascular Permeability Assay Kit, ML) as previously described. [14] Briefly, EC on transwell inserts were exposed to gVPLA 2 (500 nM) or lyso-PC (1-30 µM) for two hours. FITC-labeled dextran (~40 kDa) was added to the luminal compartment for an additional two hours, and FITC-dextran clearance across the filter to the abluminal compartment was measured by relative fluorescence excitation at 485 nm and emission at 530 nm. Data were expressed as arbitrary fluorescence units.
Immunofluorescence
EC were grown on gelatinized cover slips before exposure to various conditions as described for individual experiments. EC were then fixed in 3.7% formaldehyde for 10 minutes, permeabilized with 0.25% Triton-X100 for five minutes, washed in PBS, blocked with 2% BSA in TBS-T for one hour, and then incubated for one hour at room temperature with the primary antibody of interest. After washing, EC were incubated with the appropriate secondary antibody conjugated to immunofluorescent dyes (or Texas-Red conjugated phalloidin for actin staining) for 1 hour at room temperature. Final washing was performed with TBS-T, and coverslips were mounted using Prolong Anti-Fade Reagent (Invitrogen) and analyzed using a Nikon Eclipse TE2000-s inverted microscope and Adobe Photoshop 7.0.
Immunoblotting analysis
Cultured EC were stimulated with either vehicle control or 500 nM gVPLA 2 for 1-15 min at 37°C. Treated EC were subsequently washed with cold Ca 2+ /Mg-free PBS and lysed with 0.3% SDS lysis buffer containing protease inhibitors (1 mM EDTA, 1 mM PMSF, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 0.2 TIU/ml aprotinin, 10 μM leupeptin, 5 μM pepstatin A). Sample proteins were separated with 4-15% SDS-PAGE gels (Bio-Rad, Hercules, Calif.) and transferred onto Immobilion-P PVDF membranes (Millipore). Membranes were then immunoblotted with primary antibodies (1:500-1000, 4°C, overnight) followed by secondary antibodies conjugated to HRP (1:5000, room temperature, 30 minutes). Protein expression was detected with enhanced chemiluminescence (Pierce ECL or SuperSignal West Dura, Pierce Biotechnology, Rockford, Ill.) on Biomax MR film (Kodak, Rochester, NY). Multiple blots were scanned and quantitatively analyzed using ImageQuant software (v5.2; Molecular Dynamics, Piscataway, N.J.).
determination of toxicity on human pulmonary artery endothelial cells
To determine the cytotoxic effect of membrane hydrolysis products on EC, propidium iodide staining was assessed as previously described for eosinophils. [17] Aliquots of 0.5 × 10 6 EC were incubated for 30 minutes at 37°C with 10-50 µM lyso-PC, lyso-PG, LPA, or arachidonic acid in a total volume of 250 µl. Propidium iodide at 5 µg/ml was added to the medium of drug-treated cells, and the cell suspension was immediately analyzed by flow cytometry, or plated for fluorescent imaging. Red fluorescence intensity was determined by flow cytometry on at least 10,000 cells from each sample, and the percentage of stained cells was analyzed using the Cellquest software.
Statistical analysis
Data were expressed as mean + SEM. Statistical analyses among groups were performed using standard Student's t-test. Statistical significance in all cases was defined at P<0.05.
RESultS gVPlA 2 membrane hydrolysis products do not induce EC barrier disruption
Prior studies have demonstrated that 0-500 nM recombinant gVPLA 2 increases the permeability of cultured microvascular and macrovascular human pulmonary EC in a concentration-dependent fashion. [14] Differential barrier properties of these two classes of EC have been described in some models. [18, 19] Our data indicate that gVPLA 2 disrupts human lung microvascular EC (HLMVEC) permeability in a qualitative manner similar to macrovascular human pulmonary artery EC (HPAEC). In this study, we chose to use HPAEC for most analyses because the magnitude of disruption induced by gVPLA 2 in general is greater than that observed in microvascular cells. To determine the effects of gVPLA 2 and individual gVPLA 2 hydrolysis products on human pulmonary EC barrier function, we first measured the transendothelial monolayer resistance (TER), a highly sensitive method for obtaining real-time permeability data. [15, 16] As previously observed, [14] 500 nM of gVPLA 2 causes a rapid decrease in TER (which correlates with increased permeability and disruption of barrier function) in both HPAEC and HLMVEC by ~30-50% for>10 hours ( Fig. 1A-C ). In contrast, multiple hydrolysis products known to be produced by gVPLA 2 activity at the cell membrane (arachidonic acid [AA], lysophosphatidylcholine [lyso-PC], lysophosphatidylglycerol [lyso-PG], lysophosphatidic acid [LPA]) [7, 8] did not decrease TER when added individually to HPAEC at concentrations<1 µM ( Fig.  1A ). Further TER studies revealed that AA, Lyso-PG, and LPA all failed to significantly alter HPAEC barrier function until their concentration was>10 µM (data not shown).
Lyso-PC is expected to be the major lysophospholipid produced by gVPLA 2 at the cell surface because mammalian cell membranes are enriched in its precursor, PC, and gVPLA 2 demonstrates greater hydrolytic activity for PC than other glycerophospholipids. [20] In additional TER studies, at least 30 µM lyso-PC was required to increase permeability in both HPAEC and HLMVEC ( Fig. 1B and C) .
To determine the effects of lyso-PC on EC permeability to larger particles, a transwell assay utilizing labeled dextran (~40 kD) was employed. As previously demonstrated for HPAEC, [14] gVPLA 2 (500 nM) significantly increased HLMVEC permeability to dextran as a cumulative measurement after two hours of incubation ( Fig. 2) .
However, lyso-PC did not increase HLMVEC permeability to larger particles at concentrations less than 30 µM ( Fig.  2) . Interestingly, 30 µM lyso-PC induced dramatically more permeability in HLMVEC as measured by labeled dextran than by TER ( Figures 1C and 2) . The cause of this quantitative discrepancy is unclear, but it likely relates to the differential cell properties assessed by each technique. The TER assay uses the passage of electrical current across the cell monolayer to estimate permeability. This current can pass via paracellular pathways as in the dextran assay, but it also can transit directly through the cells, or pass between the cells and the underlying matrix. [21] In certain situations, the resistance to current under the cells can dominate the effects of the paracellular compartment so that the overall TER reading reflects this property to a greater extent than the flow of current between the cells, [22] thus potentially leading to a discrepancy with labeled macromolecule assessments of permeability. However, regardless of the assay used, all the data reported here are consistent with the primary observation that lyso-PC produced by gVPLA 2 activity is unlikely to be a primary mediator of EC permeability induced by gVPLA 2 .
Immunofluorescent analysis was performed to assess the effects of lyso-PC on EC cytoskeletal structure. Consistent with prior observations, [14] incubation of HPAEC with gVPLA 2 (500 nM, 30 minutes) produced increased actin stress fibers, intercellular gap formation, and disruption of peripheral VE-cadherin staining (the major cell-cell junction protein in EC; [23] Fig. 3 ). These structural changes are known to cause increased permeability in cultured EC. [6] In contrast, HPAEC incubated with lyso-PC at concentrations<30 µM exhibited stable or increased cortical actin staining and intact intercellular VE-cadherin distribution (Fig. 3) , a pattern indicative of intact barrier function. Although 30 µM of lyso-PC resulted in some stress fibers and large gap formation between EC, this high concentration produced cell toxicity not seen with gVPLA 2 alone. Propidium iodide staining demonstrated significantly increased toxicity in HPAEC after incubation with 30 µM lyso-PC (50% of cells with positive uptake) compared with vehicle controls (20.5%, P<0.05) or those incubated with 500 nM gVPLA 2 (24%, P<0.05; Fig. 4 ). In addition, three other major products of gVPLA 2 hydrolysis (Lyso-PG, LPA, and arachidonic acid) induced significant toxicity at concentrations at which they increase HPAEC permeability (30-50 µM; Fig. 5 ). These findings do not support a role for lyso-PC, lyso-PG, LPA, or arachidonic Intracellular signaling pathways are not required for gVPlA 2 
-induced EC barrier disruption
Previous studies in various cell types have demonstrated that gVPLA 2 stimulates upregulation of multiple downstream signaling cascades, including the ERK, p38, Akt, and cytoplasmic gIVaPLA 2 pathways. [24, 25] To determine the effects of gVPLA 2 on these pathways in HPAEC, Western blot analyses were performed at various timepoints following gVPLA 2 stimulation. Phosphorylated ERK (indicative of ERK activation) was significantly increased within 3 minutes in HPAEC following gVPLA 2 stimulation (Fig. 6A) , while no activation of p38 or Akt occurs ( Fig.  6B and C) . Downstream cytoplasmic gIVaPLA 2 also was rapidly activated following gVPLA 2 (Fig. 6D) . Thus, the ERK and gIVaPLA 2 pathways are induced in HPAEC by gVPLA 2 during the timeframe in which the initiation of permeability occurs (Fig. 1A) . Because lyso-PC is the major lysophospholipid produced by gVPLA 2 , its effects on ERK activation in pulmonary EC were assessed. Lyso-PC (10 µM) rapidly activated ERK in HPAEC within 3-5 minutes, which declined thereafter ( Fig. 7 ). Thus, it is possible that some acid generation by gVPLA 2 as a mechanistic contributor to pulmonary EC permeability induced by gVPLA 2 in vitro. portion of the ERK phosphorylation induced by gVPLA 2 is a result of lyso-PC generation.
We next determined if pharmacologic inhibition of any of these signaling pathways affected pulmonary EC barrier disruption by gVPLA 2 . HPAEC were preincubated with UO126 (ERK inhibitor), SB203580 (p38 inhibitor), LY294002 (PI3 kinase inhibitor), or TFMK (gIVPLA 2 inhibitor) for 30 minutes prior to stimulation with gVPLA 2 . Inhibitor concentrations were selected based upon preliminary experiments demonstrating their effectiveness in blocking agonist-induced activation (Figure 8 demonstrates that 10 µM UO126 prevents ERK phosphorylation by gVPLA 2 ). Pooled data from multiple TER experiments revealed that HPAEC barrier disruption by gVPLA 2 is not dependent on activation of any of these pathways (Fig. 8 ). In addition, immunofluorescent analysis of EC structure demonstrated that ERK inhibition (UO126, 10 µM) did not block the increased actin stress fibers, intercellular gap formation, and disruption of peripheral VE-cadherin produced by gVPLA 2 (500 nM, five minutes; Fig. 9 ). In fact, HPAEC incubated with both UO126 and gVPLA 2 exhibited more pronounced disruption of VE-cadherin staining than that caused by gVPLA 2 alone (Fig. 9) . These results indicate that pulmonary EC permeability induced by gVPLA 2 in vitro does not require ERK, p38, Akt, or gIVaPLA 2 signaling. gVPlA 2 internalization is not required for EC barrier disruption gVPLA 2 also enters mammalian cells through heparin proteoglycan binding at the outer surface to act intracellularly on the perinuclear membrane. This activation generates bioactive lipid mediators both by cytosolic gIVaPLA 2dependent [26, 27] and gIVaPLA 2 -independent mechanisms. [28, 29] However, internalization of gVPLA 2 into EC did not cause increased membrane permeability. HPAEC were preincubated for several hours with heparinase I to remove cell surface heparin sulfate glycosaminoglycans as previously described. [30] To ensure adequate removal of the cell surface heparin sulfate moieties, we used significantly higher concentrations of heparinase I in this study (1-10 units/ml) compared with prior reports (15 mU/ml). [30] Baseline HPAEC TER was not affected by incubation with heparinase I (data not shown). Despite pretreatment with these high concentrations of heparinase I, HPAEC barrier disruption by gVPLA 2 was not inhibited (Fig. 10) . Rather, Figure 9 : ERK inhibition fails to block the effects of gVPLA 2 on endothelial structure. HPAEC were preincubated for 30 minutes with vehicle or UO126 (10 µM). The cells were then stimulated for 5 minutes with either vehicle control or gVPLA 2 (500 nM) and then fixed and stained for F-actin (red) or VE-cadherin (green) as described in the Materials and Methods section. The F-actin and VE-cadherin images represent the same cell field for each condition. Arrows indicate intercellular gaps or disruption of intercellular VE-cadherin bands. Images are representative of three to four independent experiments. induced by LPS in vitro. [14] Animal studies by other groups further support an important role for gVPLA 2 in the pathophysiology of ALI. Transgenic mice overexpressing gVPLA 2 develop fatal respiratory failure shortly after birth that pathophysiologically resembles ALI. [31] Recent reports using the general sPLA 2 inhibitor LY374388 to attenuate LPS-induced ALI in mice [13] or acute cardiogenic pulmonary edema in a mouse model [32] suggest that this protective effect is largely due to gVPLA 2 inhibition. Thus, gVPLA 2 may be a critical target for therapeutic modulation of pathways responsible for the development of pulmonary edema, and further exploration of its mechanistic effects is warranted.
We have recently reported that the addition of recombinant gVPLA 2 to the culture media rapidly induces sustained disruption of EC barrier function in both macrovascular and microvascular pulmonary EC; [14] however, the mechanism by which gVPLA 2 produced this effect was not defined. Although the structurally related enzyme, gIIaPLA 2 , has been suggested to participate in induction of ALI, [33] it did not increase pulmonary EC permeability in vitro. [14] gVPLA 2 has much higher affinity than gIIaPLA 2 for zwitterionic phosphatidylcholine-rich outer plasma membranes and therefore greater ability to generate free fatty acids and lysophospholipids at these surfaces. [34] gVPLA 2 is unique among sPLA 2 enzymes in having a dual ability binding to bind cell membranes via two mechanisms, through cationic residues at the C-terminus which bind to cell surface heparan sulfate proteoglycan (like gIIaPLA 2 ), and via direct binding with membrane phosphatidylcholine (like gXPLA 2 ). [34] These properties make gVPLA 2 a more effective paracrine agent during inflammation than gIIaPLA 2 because the former enzyme exhibits greater transcellular lipolytic activity [35] These differences may explain why attempts to modulate the type gIIaPLA 2 form with the relatively specific inhibitor LY315920NA/S-5920 failed to improve mortality in a study of 250 patients with severe sepsis [36] and suggest that gVPLA 2 may be a better target for ALI therapy.
there was a trend toward increased barrier dysfunction after gVPLA 2 in EC pretreated with the higher concentration of heparinase I (10 units/ml, Fig. 10 ), suggesting that inhibition of gVPLA 2 internalization increases permeability.
dISCuSSIoN
The objective of this investigation was to characterize in vitro the pathway responsible for disruption of pulmonary EC barrier function caused by gVPLA 2 . We have reported previously that inhibition of gVPLA 2 by specific monoclonal antibody or genetic deletion of gVPLA 2 blocks ALI caused by LPS in mice, [12] while gVPLA 2 blocking antibody prevents pulmonary EC barrier disruption
Our results now further elucidate and simplify the mechanism by which gVPLA 2 causes pulmonary EC permeability in vitro. We investigated the hypothesis that the products of membrane hydrolysis generated by gVPLA 2 are the primary agents that initiate subsequent events leading to EC barrier dysfunction. Major products produced by gVPLA 2 activity include arachidonic acid (AA), lysophosphatidylcholine (lyso-PC), lysophosphatidylglycerol (lyso-PG), and lysophosphatidic acid (LPA) [7, 8] Lyso-PC is expected to be the major lysophospholipid produced by gVPLA 2 at the cell surface because mammalian cell membranes are enriched in its precursor, phosphatidylcholine, and gVPLA 2 demonstrates greater hydrolytic activity for PC than other glycerophospholipids. [20] Prior work by others has demonstrated increased permeability caused by lyso-PC in human dermal microvascular EC and bovine pulmonary microvessel EC, [37] human coronary artery EC, [38] and human gastric epithelial cells. [39] However, in all these studies,>10 µM lyso-PC was needed to increase permeability.
In our study, neither lyso-PC nor any of the other products studied (AA, lyso-PG, LPA) disrupt pulmonary EC barrier function at concentrations similar to gVPLA 2 alone (Fig. 1A) . They are able to increase permeability in both macro-and microvascular pulmonary EC only at relatively high concentrations (> 30 µM) ( Figs. 1 and 2) that are associated with cell toxicity (Figs. 4 and 5 ). Lyso-PC concentrations in this range previously have been shown to be toxic to eosinophils. [17] Propidium iodide staining demonstrates significantly increased toxicity in HPAEC after incubation with 30 µM lyso-PC (50% of cells with positive uptake) compared with vehicle controls (20.5%, P<0.05) and 500 nM gVPLA 2 (24%, P<0.05) (Fig. 4) . Moreover, three of the other major products of gVPLA 2 hydrolysis (Lyso-PG, LPA, and AA) induce significant toxicity within the concentration range at which they begin to increase HPAEC permeability (30-50 µM) ( Fig. 5 ). Because gVPLA 2 alone does not induce cell toxicity at the range of concentrations associated with permeability ( Fig. 4) , it is unlikely that it generates membrane hydrolysis products sufficient to produce barrier dysfunction.
It previously has been reported that albumin and other serum proteins can bind to Lyso-PC to inhibit its bioactivity in assays of EC permeability. [37] In this study, lyso-PC concentrations as low as 2 µM significantly decreased TER in human dermal microvascular EC when the concentration of albumin in the media was lowered. [37] However, our TER experiments were performed in serum free media without albumin, which eliminates any potential inhibitory effect on lyso-PC bioavailability by these proteins. Therefore, human pulmonary EC appear to be less sensitive to barrier disruption by lyso-PC than human dermal EC. Consistent with this observation, lyso-PC infusion failed to increase pulmonary microvascular permeability (assessed by fluid filtration coefficient (Kf)) in isolated perfused dog lungs. [40] These data do not support a role for lyso-PC or other gVPLA 2 membrane hydrolysis products as important mechanistic contributors to pulmonary EC permeability induced by gVPLA 2 . However, it is important to consider the limitations of our current findings. Given that membrane hydrolysis by gVPLA 2 produces dozens of products, [7, 8] the possibility exists that some of these other compounds may participate in barrier disruption. It is not feasible to test every possible hydrolysis product. Accordingly, we chose to focus on those likely generated in the highest concentrations (e.g., lyso-PC).
Previous studies in various cell types have demonstrated that gVPLA 2 stimulates upregulation of multiple intracellular signaling cascades, including the ERK, p38, Akt, and cytoplasmic gIVaPLA 2 pathways. [24, 25] Although our results demonstrate rapid activation of ERK and gIVaPLA 2 in HPAEC following gVPLA 2 stimulation (Fig. 6 ), pharmacologic inhibition of these pathways fails to block barrier disruption by gVPLA 2 (Fig. 8 ) or structural cytoskeletal changes ( Fig. 9 ). Although ERK activation occurs in association with multiple barrier-regulatory agonists in EC, this activity is not always necessary for changes in permeability. For example, pharmacologic ERK inhibition attenuates barrier disruption induced by ADAM-15 in HUVEC, [41] but not permeability increases induced by nocodazole in bovine PAEC, [42] despite both agonists producing significant ERK phosphorylation. Differences in cell type and/or agonistspecific activation by other complementary pathways likely account for this variation in ERK effects. Our data do not support a functional role for ERK signaling in pulmonary EC permeability induced by gVPLA 2 (Fig. 8 ). Activation of cytosolic gIVaPLA 2 increases intracellular AA levels leading to the production of eicosanoids and other inflammatory signaling molecules, [43] and pharmacologic inhibition of gIVaPLA 2 or its genetic deletion partially protects against ALI in mice. [44, 45] However, these protective effects in vivo could be due to inhibition of gIVaPLA 2 signaling in PMNs and other immune cells, as little data exist that demonstrate a direct role of gIVaPLA 2 in EC permeability. Data presented here argue against a functional role for gIVaPLA 2 signaling in pulmonary EC permeability induced by gVPLA 2 in vitro ( Fig. 8 ).
Although gVPLA 2 can enter mammalian cells in a heparin proteoglycan-dependent manner and act intracellularly on the perinuclear membrane to generate additional bioactive lipid mediators through both cytosolic gIVaPLA 2 -dependent [26, 27] and gIVaPLA 2 -independent mechanisms, [28, 29] this cellular uptake does not appear to be necessary for gVPLA 2 to cause increased permeability. Removal of EC surface heparin sulfate glycosaminoglycans with high concentrations of heparinase I fails to block HPAEC TER decrease by gVPLA 2 (Fig. 10 ).
Our results suggest that gVPLA 2 increases pulmonary EC permeability through direct action at the EC membrane that does not require membrane hydrolysis products, gVPLA 2 internalization, or downstream intracellular signaling. We previously have noted increased actin stress fiber formation and adherens junction disruption induced by gVPLA 2 in human pulmonary EC. [14] One possibility is that direct membrane action of gVPLA 2 results in pore formation and subsequent calcium influx which can result in MLCK and/ or Rho activation, both of which can produce stress fiber formation and junctional disassembly. [6] Another potential explanation is that gVPLA 2 activity disrupts the cell surface caveolin-enriched microdomains that are necessary for optimal EC barrier function. [46, 47] Detailed studies are ongoing to more precisely determine the mechanisms responsible for mediating increased EC permeability caused by gVPLA 2 action at the cell membrane.
